Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26)	Vycross 20 mg/ml HA (VYC-20)	Overall satisfaction of the patients	1624	1833	In this first direct comparison of CPM-26 and VYC-20, the majority of subjects were satisfied with both treatments throughout the study. Patient-reported outcome measures identified a trend in favor of CPM-26.
Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26)	Vycross 20 mg/ml HA (VYC-20)	Improvement according to the patients at the M12 and M18 visits	13844	14001	At both the M12 and M18 visits, more CPM-26-treated subjects considered themselves much improved or very much improved compared with VYC-20-treated subjects.
Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26)	Vycross 20 mg/ml HA (VYC-20)	Improvement according to the patients at the M12 and M18 visits	13844	14000	At both the M12 and M18 visits, more CPM-26-treated subjects considered themselves much improved or very much improved compared with VYC-20-treated subjects
Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26)	Vycross 20 mg/ml HA (VYC-20)	GAIS Scores	14002	14125	Overall, the majority of subjects were satisfied with both treatments throughout the study with a trend in favor of CPM-26.
Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26)	Vycross 20 mg/ml HA (VYC-20)	Overall satisfaction of the patients	14002	14125	Overall, the majority of subjects were satisfied with both treatments throughout the study with a trend in favor of CPM-26.
Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26)	Vycross 20 mg/ml HA (VYC-20)	GAIS Scores	12498	12665	At M3 and M12 after treatment, GAIS scores indicated that the majority of subjects were at least improved compared with baseline whether treated with CPM-26 or VYC-20.
